Phase 3 Recruiting Network
This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil \[5-FU\] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus s…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06998940
Sites in California: - Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- Sutter Auburn Faith Hospital — Auburn, California
- Sutter Cancer Centers Radiation Oncology Services-Auburn — Auburn, California
- Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
Phase 3 Recruiting Network
This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of som…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06807437
Sites in California: - City of Hope Comprehensive Cancer Center — Duarte, California
- UC San Diego Moores Cancer Center — La Jolla, California
- Veterans Affairs Loma Linda Healthcare System — Loma Linda, California
- USC / Norris Comprehensive Cancer Center — Los Angeles, California
- UC San Diego Medical Center - Hillcrest — San Diego, California
Phase 2, Phase 3 Recruiting Industry
Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ducta…
Sponsor: Pfizer
NCT ID: NCT06989437
Sites in California: - UC San Diego Medical Center - Encinitas — Encinitas, California
- Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- UCI Health - Irvine — Irvine, California
- UC San Diego Koman Family Outpatient Pavilion — La Jolla, California
- UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion) — La Jolla, California
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Sponsor: Incyte Corporation
NCT ID: NCT07522073
Sites in California: - Investigative Site US051 — Duarte, California
- Investigative Site US085 — Fullerton, California
- Investigative Site US054 — La Jolla, California
- Investigative Site US086 — Long Beach, California
- Investigative Site US027 — Los Angeles, California
Phase 2, Phase 3 Recruiting Industry
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Sponsor: Exelixis
NCT ID: NCT06943755
Sites in California: - Cedars-Sinai Medical Center — Beverly Hills, California
- Norris Comprehensive Cancer Center — Los Angeles, California
- Stanford Cancer Center — Palo Alto, California
- UCLA Health - Santa Monica Cancer Care — Santa Monica, California
- Kaiser Permanente Medical Center — Vallejo, California
Phase 3 Recruiting Industry
Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic). The standard treatment is chemotherapy, but other treatments are needed to imp…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07409272
Sites in California: - Crosson Cancer Institute at Providence St. Jude Medical Center in Fullerton — Fullerton, California
- Cedars-Sinai - Cedars-Sinai Medical Center — Los Angeles, California
- Hoag Mem Hosp Presbyterian — Newport Beach, California
Phase 3 Recruiting Industry
The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Sponsor: RenovoRx
NCT ID: NCT03257033
Sites in California: - VA Loma Linda Healthcare System — Loma Linda, California
- Sutter Cancer Center Sacramento — Sacramento, California
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT07252232
Sites in California: - UC San Diego Moores Cancer Center — La Jolla, California
- Cedars-Sinai Cancer at Cedars-Sinai Medical Center — Los Angeles, California
- University of California, Los Angeles — Los Angeles, California
- Stanford Cancer Institute — Palo Alto, California
- University of California, San Francisco — San Francisco, California
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.
Sponsor: Immuneering Corporation
NCT ID: NCT07562152
Sites in California: - City of Hope — Duarte, California
Phase 3 Recruiting Industry
A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differenti…
Sponsor: Crinetics Pharmaceuticals Inc.
NCT ID: NCT07087054
Sites in California: - Hoag Memorial Hospital Presbyterian — Newport Beach, California
Phase 2, Phase 3 Recruiting Industry
The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcino…
Sponsor: Panbela Therapeutics, Inc.
NCT ID: NCT05254171
Sites in California: - Providence Medical Foundation — Fullerton, California
Phase 3 Recruiting Industry
The study is designed to assess whether glufosfamide provides additional survival benefit as compared to bolus 5-FU in patients with metastatic pancreatic cancer who have already progressed or failed therapy on a gemcitabine based first li…
Sponsor: Eleison Pharmaceuticals LLC.
NCT ID: NCT01954992
Sites in California: - Innovative Clinical Research Institute — Whittier, California
Phase 3 Recruiting Industry
The aim of this Phase 3 study is to evaluate the efficacy of Kinisoquin™ as compared to the placebo in prevention of thromboembolic events in patients with metastatic or locally advanced pancreatic cancer.
Sponsor: Quercis Pharma AG
NCT ID: NCT06861088
Sites in California: - Ventura Clinical Trials — Ventura, California
Phase 2 Recruiting NIH
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04858334
Sites in California: - Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- PCR Oncology — Arroyo Grande, California
- Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- Palo Alto Medical Foundation-Fremont — Fremont, California
Phase 2 Recruiting Network
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05040360
Sites in California: - Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- PCR Oncology — Arroyo Grande, California
- Tower Cancer Research Foundation — Beverly Hills, California
- Keck Medicine of USC Buena Park — Buena Park, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
Phase 2 Recruiting Academic/Other
This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has s…
Sponsor: Sameek Roychowdhury
NCT ID: NCT06906562
Sites in California: - Ohio State University Telemedicine — Fresno, California
- Ohio State University-Telemedicine — Los Angeles, California
- Ohio State University-Telemedicine — San Diego, California
- Ohio State University-Telemedicine — San Francisco, California
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in California: - USC Norris Comprehensive Cancer Center — Los Angeles, California
- Sansum Clinic — Santa Barbara, California
- Providence Medical Foundation — Santa Rosa, California
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in partici…
Sponsor: Genentech, Inc.
NCT ID: NCT05968326
Sites in California: - USC Norris Comprehensive Cancer Center — Los Angeles, California
- USC Norris Cancer Center — Newport Beach, California
- University of California, San Francisco (UCSF) — San Francisco, California
- University of California Los Angeles — Santa Monica, California
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in California: - UC San Diego Moores Cancer Center — La Jolla, California
- Cedars-Sinai Cancer at Cedars-Sinai Medical Center — Los Angeles, California
- UCLA Hematology/Oncology- Santa Monica — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in California: - City of Hope — Duarte, California
- UC IRVINE Health — Orange, California
- UC Davis Comprehensive Cancer Center — Sacramento, California
- Stanford Cancer Institute — Stanford, California
Phase 1, Phase 2 Recruiting Industry
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT05379985
Sites in California: - UC Irvine/Chao Family Comprehensive Cancer Center — Orange, California
- UCLA — Santa Monica, California
Phase 2 Recruiting Industry
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer
Sponsor: Verastem, Inc.
NCT ID: NCT07644559
Sites in California: - START- Los Angeles — Los Angeles, California
- Cedars-Sinai Medical Center — Los Angeles, California
- Valkyrie Clinical Trials — Los Angeles, California
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in California: - Children's Hospital Los Angeles — Los Angeles, California
- Children's Hospital of Orange County — Orange, California
- Lucile Packard Children's Hospital Stanford University — Palo Alto, California
- UCSF Medical Center-Mission Bay — San Francisco, California
Phase 1, Phase 2 Recruiting Industry
The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-del…
Sponsor: Bayer
NCT ID: NCT06914128
Sites in California: - City of Hope - Duarte Cancer Center — Duarte, California
- UCLA Health Bowyer Oncology Center — Los Angeles, California
- UCSF Helen Diller Medical Center at Parnassus Heights - Neurology — San Francisco, California
- Stanford University Medical Center - Neurology — Stanford, California
Phase 2 Recruiting Industry
This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BM…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07492680
Sites in California: - Local Institution - 0096 — San Francisco, California